Zyvox 2 mg/ml Solution for Infusion

  • Name:

    Zyvox 2 mg/ml Solution for Infusion

  • Company:
    info
  • Active Ingredients:

    Linezolid

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/02/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 10/2/2017
print

Print ViewKeyword Search SmPC

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Relpax 40mg Film-Coated Tablets Active Ingredients Eletriptan hydrobromide
Medicine Name Retacrit solution for injection in pre filled syringe Active Ingredients Epoetin Zeta
Medicine Name Revatio 0.8 mg/ml solution for injection Active Ingredients sildenafil citrate
Medicine Name Revatio 10 mg/ml powder for oral suspension Active Ingredients sildenafil citrate
Medicine Name Revatio 20 mg film-coated tablets Active Ingredients sildenafil citrate
Medicine Name Salazopyrin EN Tablets Active Ingredients Sulfasalazine
Medicine Name Salazopyrin Tablets Active Ingredients Sulfasalazine
Medicine Name Sildenafil Pfizer 25mg, 50mg, 100mg film–coated tablets Active Ingredients sildenafil citrate
Medicine Name Solu-Cortef Powder for Solution for Injection or Infusion 100 mg Active Ingredients Hydrocortisone sodium succinate
Medicine Name Solu-Medrone 1000mg Active Ingredients Methylprednisolone sodium succinate
Medicine Name Solu-Medrone 125 mg Active Ingredients Methylprednisolone sodium succinate
Medicine Name Solu-Medrone 40mg Active Ingredients Methylprednisolone sodium succinate
Medicine Name Solu-Medrone 500 mg Active Ingredients Methylprednisolone sodium succinate
Medicine Name Somavert 10mg, 15mg, 20mg, 25mg and 30mg Powder and Solvent for Solution for Injection Active Ingredients Pegvisomant
Medicine Name SUTENT 12.5mg, 25mg, 37.5mg and 50mg Hard Capsules Active Ingredients Sunitinib malate
Medicine Name Synarel Nasal Spray Active Ingredients nafarelin acetate
Medicine Name TicoVac 0.5 ml Suspension for injection in a prefilled syringe Active Ingredients Tick borne encephalitis vaccine
Medicine Name TicoVac Junior 0.25 ml Suspension for injection in a pre-filled syringe Active Ingredients Tick borne encephalitis vaccine
Medicine Name Tobramycin 40 mg/ml Solution for Injection Active Ingredients Tobramycin
Medicine Name TORISEL 30 mg concentrate and diluent for solution for infusion Active Ingredients Temsirolimus
Medicine Name Toviaz Prolonged-Release Tablets 4mg & 8mg Active Ingredients Fesoterodine Fumarate
Medicine Name Trazimera - 150mg & 420mg powder for solution for infusion Active Ingredients Trastuzumab
Medicine Name Trosyl 283mg/ml Nail Solution Active Ingredients Tioconazole
Medicine Name TRUMENBA Active Ingredients Meningococcal group B vaccine (recombinant, adsorbed)
Medicine Name Tygacil 50mg powder for solution for infusion Active Ingredients Tigecycline
176 - 200 of 227 items.Total: 10 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 February 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals
  • Correction of spelling/typing errors

Updated on 13 February 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 10 February 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Editorial, formatting and QRD changes to section 1, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 5.1, 5.2, 5.3, 6.1, 6.4, 6.5, 6.6, 10

Updated on 10 February 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 12 January 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 11 July 2016 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 13 October 2014 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.6 – Fertility, pregnancy and lactation: added wording Fertility In animal studies, linezolid caused a reduction in fertility (see section 5.3).

Section 4.8 Undesirable effects updated in relation to the frequency of side effects

Updated on 8 October 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 31 October 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 2 and update to 6.4

Updated on 24 October 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to improve clarity and readability

Updated on 14 October 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text
  • Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to MA Holder
Change to licence holder

Updated on 9 October 2013 PIL

Reasons for updating

  • Change of licence holder
  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 9 July 2013 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 27 April 2012 PIL

Reasons for updating

  • Change to packaging
  • Introduction of new pack/pack size

Updated on 18 October 2011 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 23 June 2011 PIL

Reasons for updating

  • Change to information about driving or using machinery
  • Change to side-effects

Updated on 12 November 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 11 November 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 4 December 2009 PIL

Reasons for updating

  • Change to side-effects

Updated on 28 July 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions

Updated on 20 November 2008 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 18 August 2008 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 18 May 2007 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to side-effects
  • Change to warnings or special precautions for use

Updated on 15 January 2007 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 22 June 2005 PIL

Reasons for updating

  • Change to side-effects

Updated on 11 April 2005 PIL

Reasons for updating

  • Change to dosage and administration

Updated on 23 March 2005 PIL

Reasons for updating

  • Change to dosage and administration
  • Change to date of revision

Updated on 12 January 2005 PIL

Reasons for updating

  • New PIL for medicines.ie